AdvanCell to participate in Jefferies Global Healthcare Conference in London
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025.
The AdvanCell team – Andrew Adamovich (CEO),Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) - will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion.
“It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We look forward to engaging with investors and partners in London to discuss these important developments.”
About 212Pb-ADVC001
212Pb-ADVC001 is a proprietary and patented PSMA-targeting radioligand with optimized physicochemical properties and labelled with 212Pb, an alpha-emitting payload (radionuclide) with a high dose rate, 10.6 hour half-life and simple decay scheme. 212Pb-ADVC001 is designed to deliver radiation at a cellular level to effectively kill prostate cancer cells while minimizing toxicity.
212Pb-ADVC001 is being evaluated in the TheraPb trial (NCT05720130) – a prospective, open-label Phase 1/2 dose-escalation and expansion study to assess the efficacy and safety of 212Pb-ADVC001 in men with prostate cancer.
The Phase 1b dose escalation showed a compelling therapeutic index for 212Pb-ADVC001, demonstrating encouraging safety and promising anti-tumor activity, including no dose-limiting toxicities or treatment-related serious adverse events, 80% PSA50 response at doses ≥ 160 MBq and 100% objective response rate (ORR) in patients with RECIST-measurable lesions, including two complete responses (see results presented at ESMO 2025 here).
Phase 2 will utilize a randomized dose-response design and adaptive dosing elements to evaluate optimal dosing strategies of 212Pb-ADVC001 in PSMA-positive mCRPC and in mHSPC.
About AdvanCell
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By leveraging its proprietary Lead-212 platform, advanced and scalable manufacturing capabilities and world-class clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for patients with cancer globally. For more information, visit www.advancell.com.au and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251111303258/en/
Contacts
Andrew Adamovich, CEO
contact@advancell.com.au
For media inquiries, please contact:
MEDiSTRAVA (in the UK)
Mark Swallow, Frazer Hall, Sylvie Berrebi
advancell@medistrava.com
+44 (0)20 3928 6700
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla and Airbridge Partner to Deliver Unified Mobile and Web Performance Insights for Game Developers11.11.2025 16:36:00 EET | Press release
Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Airbridge, a leading unified measurement platform for mobile marketers. This strategic partnership empowers mobile game developers with precise, cross-platform performance tracking by bridging the gap between mobile marketing efforts and purchases made through the Xsolla Web Shop. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111170674/en/ (Graphic: Xsolla) As more developers turn to Web Shops to drive direct-to-consumer monetization beyond traditional app stores, understanding the full value of those off-platform transactions has become increasingly critical. With Xsolla’s new S2S integration, powered by Airbridge, developers can now gain a complete and accurate view of campaign performance, attributing web purchases as in-app events and revealing valid
Andersen Consulting Strengthens Digital Transformation Offering Through Collaboration with VaporVM11.11.2025 16:30:00 EET | Press release
Andersen Consulting expands its digital transformation and cybersecurity capabilities with the addition of collaborating firm VaporVM, a cloud-native technology firm headquartered in Dubai. Founded in 2017, VaporVM helps global enterprises navigate digital transformation through integrated cloud services, DevOps, cybersecurity, data science, and application modernization. With a focus on scalability and speed-to-market, the firm works with Fortune 500 companies and leverages their domain expertise and automation to streamline IT operations and accelerate digital outcomes. “At VaporVM, we are dedicated to helping businesses not only adopt new technologies but also reimagine what’s possible when those technologies are harnessed to drive real transformation,” said Aqeel Asim, CEO and founder of VaporVM. “Our collaboration with Andersen Consulting allows us to amplify that mission on a global scale—bringing our cloud, cybersecurity, and digital transformation expertise to new markets, and
ThreatDown Launches Nexus Partner Program, Strengthening its Channel-First Commitment11.11.2025 16:02:00 EET | Press release
ThreatDown, the corporate business unit of Malwarebytes, today announced the launch of the Nexus Partner Program, a comprehensive initiative that puts partners at the center by strengthening collaboration and creating new growth opportunities for its global network of partners. The program aligns incentives, simplifies enablement, and strengthens collaboration to ensure every reseller has the resources and support needed to deliver smarter, stronger security outcomes for customers. “At ThreatDown, being channel-first means putting our partners at the center of everything we do,” says Kendra Krause, General Manager of ThreatDown. “The Nexus Partner Program reflects that belief – the program is built to equip partners with the tools they need to succeed in a rapidly evolving cybersecurity market. When our partners win, we win.” Available globally, the program offers competitive discounts, revenue protection, marketing resources, and technical support. Unified under a single framework tha
Blue Matter Enhances Twine ™ Platform Capabilities in Response to Growing Demand11.11.2025 16:01:00 EET | Press release
Blue Matter today announced the expansion of its Twine™ data platform’s capabilities in response to accelerating demand from biopharma companies. Enhancements include thoughtful use of artificial intelligence (AI) for advanced analytics and narratives, expanded data source integrations, master data management, and broader deployment across oncology and specialty therapeutic areas. Twine™ is Blue Matter's purpose-built customer intelligence platform for healthcare and life sciences companies. It transforms complex data from disparate sources including specialty pharmacy networks, hub services, claims databases, and other third party data sources into actionable insights that drive commercial strategy and operational excellence. With generative AI at its core, Twine helps companies more effectively acquire, master, validate, and analyze data from internal and third-party sources. Persona-specific outputs enable faster, more informed decision-making. According to Deepak Gopinath, Partner
Rigaku Holdings Issues Integrated Report 202511.11.2025 16:00:00 EET | Press release
Rigaku Holdings Corporation (Headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) issued its inaugural Integrated Report 2025 (hereinafter “the Report”) on the Rigaku website. The report serves as a medium for integrated communication with all stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111995654/en/ Integrated Report cover The Report provides an overview of Rigaku’s investments, technological innovations, business activities, and global growth strategy. It also presents Rigaku’s financial and non-financial performance for the fiscal year ending December 31, 2024. Rigaku invites readers to explore the Report to learn about its contributions to global technological advancement through X-ray diffraction solutions. Rigaku continues to strive to become a “One-of-a-Kind Global Technology Company.” The full Report can be found at: https://rigaku-holdings.com/english/ir/reports/ Comment by CEO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom